Listen

Search

L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10

Press release

Cet accès s'appuie sur une analyse intermédiaire positive des données cliniques et des données précliniques à ce jour

Julho 29, 2019
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug.

Agosto 12, 2019
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

Press release

LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct.

Outubro 07, 2019
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

Press release

Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development of the program ProQR

Maio 04, 2021
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Press release

Key Updates

Abril 10, 2018
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Press release

Key updates

Maio 01, 2017
ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Abril 18, 2019
ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10

Press release

Des améliorations rapides, significatives et durables de la vision à douze mois ont été rapportéesAmélioration concordante des mesures des résultats secondaires clésLa dose d'enregistrement cible du sepofarsen a été bien tolérée avec un profil risque/bénéfice fa

Outubro 11, 2019
ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients

Press release

… ProQR Announces that QR-010 Meets the Primary Endpoint in a … LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … results of PQ-010-002 will be presented today by Noreen R. Henig M.D. and John P. Clancy M.D. at the North American …

Outubro 27, 2016
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

Abril 23, 2021

Search

Results (241 to 250 of 263)